Attovia Therapeutics, Inc.(ATTO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Attovia Therapeutics, Inc. (ATTO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ATTO is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Attovia Therapeutics, Inc. reports quarterly revenue of $450.0K, net income of $-20.7M. ATTO trades on the Nasdaq exchange and files with the SEC under CIK 2058707. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATTO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Attovia Therapeutics, Inc. directly from SEC EDGAR.